acis Arzneimittel GmbH - search results

bene-arzneimittel gmbh - pentosan polysulfate sodium - cystitis, interstitial - urologicals - elmiron is indicated for the treatment of bladder pain syndrome characterized by either glomerulations or hunner’s lesions in adults with moderate to severe pain, urgency and frequency of micturition.,

United Kingdom - English - MHRA (Medicines & Healthcare Products Regulatory Agency)

arlevert tablets

hennig arzneimittel gmbh & co. kg - cinnarizine; dimenhydrinate - oral tablet - 20mg ; 40mg

European Union - English - EMA (European Medicines Agency)

fablyn

dr. friedrich eberth arzneimittel gmbh - lasofoxifene tartrate - osteoporosis, postmenopausal - sex hormones and modulators of the genital system, - fablyn is indicated for the treatment of osteoporosis in postmenopausal women at increased risk of fracture. a significant reduction in the incidence of vertebral and non-vertebral fractures but not hip fractures has been demonstrated (see section 5.1).when determining the choice of fablyn or other therapies, including oestrogens, for a postmenopausal woman, consideration should be given to menopausal symptoms, effects on uterine and breast tissues, and cardiovascular risks and benefits (see section 5.1).

European Union - English - EMA (European Medicines Agency)

xenical

cheplapharm arzneimittel gmbh - orlistat - obesity - antiobesity preparations, excl. diet products - xenical is indicated in conjunction with a mildly hypocaloric diet for the treatment of obese patients with a body mass index (bmi) greater or equal to 30 kg/m2, or overweight patients (bmi > 28 kg/m2) with associated risk factors.treatment with orlistat should be discontinued after 12 weeks if patients have been unable to lose at least 5% of the body weight as measured at the start of therapy.